Viridian Therapeutics, Inc./DE Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Viridian Therapeutics, Inc./DE (VRDN) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $447.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-26
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $447.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $511.00K.
- 2025-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $432.00K.
- 2025-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $486.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $447.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $511.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $432.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $486.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $543.00K 10-K · filed 2025-03-03 |
| 2024-09-30 | $603.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $498.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $191.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $227.00K 10-K · filed 2024-02-27 |
| 2023-09-30 | $266.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $309.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $174.00K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $217.00K 10-K · filed 2023-03-09 |
| 2022-09-30 | $170.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |